» Articles » PMID: 22935022

Induced Pluripotent Stem Cells and Their Potential for Basic and Clinical Sciences

Overview
Date 2012 Sep 1
PMID 22935022
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Induced pluripotent stem (iPS) cells, are a type of pluripotent stem cell derived from adult somatic cells. They have been reprogrammed through inducing genes and factors to be pluripotent. iPS cells are similar to embryonic stem (ES) cells in many aspects. This review summarizes the recent progresses in iPS cell reprogramming and iPS cell based therapy, and describe patient specific iPS cells as a disease model at length in the light of the literature. This review also analyzes and discusses the problems and considerations of iPS cell therapy in the clinical perspective for the treatment of disease.

Citing Articles

Osteosarcoma: A comprehensive review of model systems and experimental therapies.

Robbins G, Vue Y, Rahrmann E, Moriarity B Med Res Arch. 2025; 12(11).

PMID: 39916749 PMC: 11801376. DOI: 10.18103/mra.v12i11.6000.


Establishment of subcutaneous transplantation platform for delivering induced pluripotent stem cell-derived insulin-producing cells.

Tran H, Rodprasert W, Padeta I, Oontawee S, Purbantoro S, Thongsit A PLoS One. 2025; 20(1):e0318204.

PMID: 39883721 PMC: 11781742. DOI: 10.1371/journal.pone.0318204.


Three-Dimensional Printing/Bioprinting and Cellular Therapies for Regenerative Medicine: Current Advances.

Sousa A, Alvites R, Lopes B, Sousa P, Moreira A, Coelho A J Funct Biomater. 2025; 16(1).

PMID: 39852584 PMC: 11765675. DOI: 10.3390/jfb16010028.


Dynamic three dimensional environment for efficient and large scale generation of smooth muscle cells from hiPSCs.

Green A, Wei Y, Warram J, Hartman Y, Geng X, Nguyen T Stem Cell Res Ther. 2024; 15(1):463.

PMID: 39627821 PMC: 11616106. DOI: 10.1186/s13287-024-04053-z.


Applications, Limitations, and Considerations of Clinical Trials in a Dish.

Mir A, Zhu A, Lau R, Barr N, Sheikh Z, Acuna D Bioengineering (Basel). 2024; 11(11).

PMID: 39593756 PMC: 11591410. DOI: 10.3390/bioengineering11111096.


References
1.
Sugii S, Kida Y, Berggren W, Evans R . Feeder-dependent and feeder-independent iPS cell derivation from human and mouse adipose stem cells. Nat Protoc. 2011; 6(3):346-58. PMC: 3089977. DOI: 10.1038/nprot.2010.199. View

2.
Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S . Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. 2008; 26(11):1269-75. DOI: 10.1038/nbt.1502. View

3.
Lee G, Papapetrou E, Kim H, Chambers S, Tomishima M, Fasano C . Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009; 461(7262):402-6. PMC: 2784695. DOI: 10.1038/nature08320. View

4.
Okahara-Narita J, Umeda R, Nakamura S, Mori T, Noce T, Torii R . Induction of pluripotent stem cells from fetal and adult cynomolgus monkey fibroblasts using four human transcription factors. Primates. 2011; 53(2):205-13. DOI: 10.1007/s10329-011-0283-1. View

5.
Montserrat N, de Onate L, Garreta E, Gonzalez F, Adamo A, Eguizabal C . Generation of feeder-free pig induced pluripotent stem cells without Pou5f1. Cell Transplant. 2011; 21(5):815-25. DOI: 10.3727/096368911X601019. View